EMA Authorised: Suliqua (insulin glargine;lixisenatide) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA authorised Suliqua, a fixed-dose combination of insulin glargine and lixisenatide, for the treatment of Type 2 diabetes mellitus; the marketing authoriz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Suliqua (insulin glargine; lixisenatide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Sanofi Winthrop Industrie. Decision date: 22/10/2024